Drug development for fibrotic diseases

Item Number: 526
Industry: Therapeutic
Category: Fibrosis, Liver Disease
Development Stage: Early Stage
Organisation Type: University
Country: South Korea
Patent: Korea, USA, Europe
Business Opportunity: Out-Licensing, Technology Transfer, Collaboration R&D


Activated hepatic stellate cells (HSCs) play a major role in the development of liver fibrosis and their activation is the target of many anti-fibrotic therapies. However, these approaches have remained ineffective mainly due to an incomplete understanding of the molecular mechanisms underlying HSC activation and the lack of target specificity of candidate drugs.

Features & Contact

Sign in and you'll be able to send enquiries about this item, view full details and save it